封面
市场调查报告书
商品编码
1698010

直接抗病毒药物市场 - 全球产业规模、份额、趋势、机会和预测,按类型、按适应症、按途径、按配销通路、按地区和竞争细分,2020-2030 年

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Indication, By Route, By Distribution Channel, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球直接抗病毒药物市场价值为 114.1 亿美元,预计到 2030 年将达到 236.1 亿美元,复合年增长率为 12.86%。由于病毒感染(尤其是C型肝炎)的盛行率不断上升,全球直接抗病毒 (DAA) 药物市场正在扩大。这些药物针对特定的病毒蛋白来抑制复製,提供了一种高效且耐受性良好的治疗选择。製药业的进步促进了下一代 DAA 的开发,其疗效更高、治疗时间更短。随着医疗保健提供者和政府优先考虑丙型肝炎消除计划,市场正在经历显着增长。联合疗法的引入进一步增强了治疗效果,降低了抗药性风险并提高了持续病毒学反应(SVR)率。扩大发展中国家获得诊断检测和治疗的机会在市场扩张中发挥着至关重要的作用。

市场概览
预测期 2026-2030
2024 年市场规模 114.1亿美元
2030年市场规模 236.1亿美元
2025-2030 年复合年增长率 12.86%
成长最快的领域 NS3/4 A蛋白酶
最大的市场 北美洲

在政府措施和非营利组织的支持下,人们对早期诊断和治疗的认识不断提高,市场也因此受益。对抗病毒药物研究的投入不断增加,促进了安全性更高的创新疗法的开发。个人化医疗的转变正在影响对有针对性的抗病毒疗法的需求,确保更高的治疗成功率。生物技术和基因研究的突破使製药公司能够设计出更精确、更有效的 DAA。与注射治疗相比,口服疗法的受欢迎程度日益提高,这推动了患者的依从性,使 DAA 成为抗病毒治疗策略的首选。研究机构和製药公司之间的合作正在加速药物开发,从而形成强大的下一代 DAA 管道。各国不断扩大的医疗基础设施和优惠的报销政策正在为市场参与者创造机会。

儘管取得了进步,但市场仍面临着治疗成本高昂的挑战,限制了低收入地区患者的治疗可及性。抗药性病毒株的出现越来越令人担忧,需要不断研究以开发更有效的配方。新的 DAA 的监管障碍和漫长的审批流程可能会延迟进入市场,影响创新週期。某些地区对有效抗病毒治疗的认知有限,导致采用率降低。仿製药的出现加剧了市场竞争,给定价策略带来了压力。透过策略定价模型、抗药性管理研究和扩大全球治疗范围来应对这些挑战对于维持市场成长至关重要。

主要市场驱动因素

高效且提高治癒率

主要市场挑战

治疗费用高昂

主要市场趋势

扩大适应症

目录

第 1 章:产品概述

第 2 章:研究方法

第三章:执行摘要

第四章:顾客之声

第五章:全球直接抗病毒药物市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依类型(NS3/4A 蛋白酶、NS5A 蛋白质、NS5B RNA 依赖性 RNA 聚合酶)
    • 依适应症(C型肝炎病毒、HIV感染/爱滋病、流感、预防)
    • 依途径(静脉注射、口服、皮下注射、外用)
    • 按配销通路(医院药房、零售药房、网路药房)
    • 按地区
    • 按公司分类(2024)
  • 产品市场图
    • 依药物类型
    • 按适应症
    • 按路线
    • 按配销通路
    • 按地区

第六章:北美直接抗病毒药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 加拿大
    • 墨西哥

第七章:欧洲直接抗病毒药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章:亚太直接抗病毒药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 日本
    • 印度
    • 澳洲
    • 韩国

第九章:南美洲直接抗病毒药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 阿根廷
    • 哥伦比亚

第十章:中东和非洲直接抗病毒药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 近期发展
  • 合併与收购
  • 产品发布

第 13 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章:竞争格局

    • 纳特科製药股份有限公司
    • Vertex 製药公司
    • 雷迪博士实验室有限公司
    • 强生公司
    • 默克公司
    • 吉利德科学公司
    • 艾伯维公司
    • 百时美施贵宝公司

第 15 章:策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 17474

Global Direct-acting Antiviral Drug Market was valued at USD 11.41 Billion in 2024 and is expected to reach USD 23.61 Billion in the forecast period with a CAGR of 12.86% through 2030. The global direct-acting antiviral (DAA) drug market is expanding due to the increasing prevalence of viral infections, particularly hepatitis C. These drugs target specific viral proteins to inhibit replication, offering a highly effective and well-tolerated treatment option. Pharmaceutical advancements have led to the development of next-generation DAAs with improved efficacy and shorter treatment durations. The market is witnessing significant growth as healthcare providers and governments prioritize hepatitis C elimination programs. The introduction of combination therapies has further enhanced treatment outcomes, reducing the risk of drug resistance and increasing sustained virologic response (SVR) rates. Expanding access to diagnostic testing and treatment in developing countries is playing a crucial role in market expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 11.41 Billion
Market Size 2030USD 23.61 Billion
CAGR 2025-203012.86%
Fastest Growing SegmentNS3/4 A Protease
Largest MarketNorth America

The market is benefiting from increasing awareness of early diagnosis and treatment, supported by government initiatives and non-profit organizations. Rising investments in antiviral drug research are fostering the development of innovative therapies with improved safety profiles. The shift toward personalized medicine is influencing the demand for targeted antiviral therapies, ensuring higher treatment success rates. Breakthroughs in biotechnology and genetic research are enabling pharmaceutical companies to design more precise and potent DAAs. The growing preference for oral therapies over injectable treatments is driving patient adherence, making DAAs a preferred choice in antiviral treatment strategies. Collaborations between research institutions and pharmaceutical firms are expediting drug development, leading to a robust pipeline of next-generation DAAs. Expanding healthcare infrastructure and favorable reimbursement policies in various countries are creating opportunities for market players.

Despite advancements, the market faces challenges related to high treatment costs, limiting accessibility for patients in low-income regions. The emergence of drug-resistant viral strains is a growing concern, requiring continuous research to develop more effective formulations. Regulatory hurdles and lengthy approval processes for new DAAs can delay market entry, impacting innovation cycles. Limited awareness in certain regions about the availability of effective antiviral treatments is slowing adoption rates. The presence of generic alternatives is intensifying market competition, putting pressure on pricing strategies. Addressing these challenges through strategic pricing models, research in resistance management, and increased global treatment outreach will be essential for sustaining market growth.

Key Market Drivers

High Efficacy and Improved Cure Rates

In recent years, the global pharmaceutical landscape has witnessed a transformative shift in the treatment of viral infections, particularly hepatitis C, due to the advent of direct-acting antiviral drugs (DAAs). These innovative medications have demonstrated exceptional efficacy, with cure rates exceeding 95%, redefining the approach to managing viral diseases.

The high efficacy of DAAs translates into significantly improved patient outcomes. For instance, a study published in JAMA Network Open reported that among patients treated with DAAs, 97.3% achieved sustained virologic response (SVR), indicating a cure. Successful DAA therapy not only clears the virus but also halts disease progression, reducing risks of liver fibrosis, cirrhosis, and hepatocellular carcinoma.

Beyond individual benefits, DAAs contribute to public health by reducing viral transmission. Effective treatment decreases viral load, thereby lowering the likelihood of spreading infections such as hepatitis B and C, which are transmitted through routes like blood contact and sexual intercourse. The World Health Organization highlights that DAAs can cure over 95% of hepatitis C cases, yet access to diagnosis and treatment remains limited globally.

DAAs also offer shorter treatment durations compared to traditional interferon-based therapies. While older regimens required treatment courses of up to 48 weeks, DAA therapies typically range from 8 to 12 weeks, enhancing patient compliance and reducing healthcare burdens. Furthermore, DAAs are associated with improved tolerability and fewer severe side effects, encouraging patients to complete their treatment regimens.

The success of DAAs has instilled confidence among patients and healthcare providers. For example, the U.S. Department of Health and Human Services notes that new hepatitis C treatments can cure approximately 95% of patients, significantly decreasing the likelihood of severe liver complications and reducing overall healthcare costs. This underscores the importance of expanding access to these life-saving therapies to achieve broader public health benefits.

Key Market Challenges

High Treatment Costs

One of the most significant challenges is the high cost of direct-acting antiviral drugs. While these medications are highly effective, their price tags can be prohibitive for many patients, especially in low- and middle-income countries. Striking a balance between recouping research and development costs and ensuring affordable access is a persistent challenge.

Key Market Trends

Expanded Indications

One significant trend in the DAA market is the exploration of expanded indications. While DAAs have been predominantly used to treat hepatitis C and B, researchers are investigating their efficacy against other viral infections. This could lead to the development of new DAA therapies targeting a broader range of viruses.

Key Market Players

  • Natco Pharma Ltd
  • Vertex Pharmaceuticals Inc
  • Dr Reddy's Laboratories Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • Gilead Sciences Inc
  • AbbVie Inc
  • Bristol-Myers Squibb Co

Report Scope:

In this report, the Global Direct-acting Antiviral Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Direct-acting Antiviral Drug Market, By Type:

  • NS3/4A Protease
  • NS5A Protein
  • NS5B RNA-Dependent RNA polymerase

Direct-acting Antiviral Drug Market, By Indication:

  • Hepatitis C Virus
  • HIV Infection/ AIDS
  • Influenza
  • Prophylaxis

Direct-acting Antiviral Drug Market, By Route:

  • Intravenous
  • Oral
  • Subcutaneous
  • Topical

Direct-acting Antiviral Drug Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Direct-acting Antiviral Drug Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Direct-acting Antiviral Drug Market.

Available Customizations:

Global Direct-acting Antiviral Drug market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Direct-acting Antiviral Drug Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
    • 5.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
    • 5.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
    • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Drug Type
    • 5.3.2. By Indication
    • 5.3.3. By Route
    • 5.3.4. By Distribution Channel
    • 5.3.5. By Region

6. North America Direct-acting Antiviral Drug Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
    • 6.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
    • 6.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
    • 6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Direct-acting Antiviral Drug Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Route
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Direct-acting Antiviral Drug Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Route
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Direct-acting Antiviral Drug Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Route
        • 6.3.3.2.4. By Distribution Channel

7. Europe Direct-acting Antiviral Drug Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
    • 7.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
    • 7.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
    • 7.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Direct-acting Antiviral Drug Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Route
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. United Kingdom Direct-acting Antiviral Drug Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Route
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. France Direct-acting Antiviral Drug Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Route
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Direct-acting Antiviral Drug Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Route
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Direct-acting Antiviral Drug Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Route
        • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Direct-acting Antiviral Drug Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
    • 8.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
    • 8.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
    • 8.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Direct-acting Antiviral Drug Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Route
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. Japan Direct-acting Antiviral Drug Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Route
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. India Direct-acting Antiviral Drug Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Route
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. Australia Direct-acting Antiviral Drug Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Route
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. South Korea Direct-acting Antiviral Drug Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Route
        • 8.3.5.2.4. By Distribution Channel

9. South America Direct-acting Antiviral Drug Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
    • 9.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
    • 9.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
    • 9.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Direct-acting Antiviral Drug Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Route
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. Argentina Direct-acting Antiviral Drug Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Route
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Colombia Direct-acting Antiviral Drug Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Route
        • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Direct-acting Antiviral Drug Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
    • 10.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
    • 10.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
    • 10.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Direct-acting Antiviral Drug Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Route
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Saudi Arabia Direct-acting Antiviral Drug Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Route
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. UAE Direct-acting Antiviral Drug Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Route
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

    • 14.6.1. Natco Pharma Ltd
    • 14.6.2. Vertex Pharmaceuticals Inc
    • 14.6.3. Dr Reddy's Laboratories Ltd
    • 14.6.4. Johnson & Johnson
    • 14.6.5. Merck & Co Inc
    • 14.6.6. Gilead Sciences Inc
    • 14.6.7. AbbVie Inc
    • 14.6.8. Bristol-Myers Squibb Co

15. Strategic Recommendations

16. About Us & Disclaimer